<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923258</url>
  </required_header>
  <id_info>
    <org_study_id>2016HNRT004</org_study_id>
    <nct_id>NCT02923258</nct_id>
  </id_info>
  <brief_title>Postoperative CCRT With Docetaxel vs Cisplatin in High Risk HNSCC</brief_title>
  <official_title>Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head &amp; Neck: a Randomized Multi-center Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized,controled, phase III, open label study of postoperative concurrent
      chemoradiotherapy with Docetaxel versus Cisplatinum for high-risk squamous cell carcinoma of
      the head and neck(HNSCC).The primary purpose of this study is to evaluate the efficacy and
      safety of concurrent chemoradiotherapy with docetaxel in HNSCC patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity profiles, graded according to the NCI CTCAE version 3.0</measure>
    <time_frame>up to 6-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Core 35 (EORTC QLQ-HN35) during the concurrent treatment</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity profiles, graded according to the NCI CTCAE version 3.0</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">387</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent Chemoradiotherapy With Docetaxel and IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent Chemoradiotherapy With Cisplatinum and IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>20mg/m2/w for 6 weeks</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatinum</intervention_name>
    <description>40mg/m2/w for 6 weeks</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>a total dose of 60Gy in 30 fractions over 6 weeks</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Histologically confirmed squamous cell carcinoma of the head and neck.Site of tumor
             origin in the oral cavity, oropharynx, larynx, or hypopharynx (excluding nasopharynx,
             or sinuses) 2. Gross total resection, with pathology demonstrating one or more of the
             following risk factors:

               1. Histologic extracapsular nodal extension

               2. Histologic involvement of â‰¥ 2 regional lymph nodes

               3. Invasive cancer seen on microscopic evaluation of the resection margin, with no
                  evidence of gross tumor residual 3. No evidence of distant metastases 4. No
                  synchronous or concurrent head and neck primary tumors 5. Karnofsky score over 60
                  6. Adequate organ function including the following:

               1. Absolute neutrophil count (ANC) &gt;= 1.5 * 10^9/l

               2. Platelets count &gt;= 100 * 10^9/l

               3. Hemoglobin &gt;= 10 g/dl

               4. AST and ALT &lt;= 2.5 times institutional upper limit of normal (ULN)

               5. Total bilirubin &lt;= 1.5 times institutional ULN

               6. Creatinine clearance &gt;= 50 ml/min

               7. Serum creatine &lt;= 1 times ULN 7.Signed written informed consent

        Exclusion Criteria:

          -  1. Evidence of distant metastasis 2. Prior chemotherapy or anti-cancer biologic
             therapy for any type of cancer, or prior radiotherapy to the head and neck region 3.
             Other previous cancer, except for in situ cervical cancer and cutaneous basal cell
             carcinoma 4. Pregnant or breast-feeding females, or females and males of childbearing
             potential not taking adequate contraceptive measures 5.Presence of an uncontrolled
             concomitant illness including, but not limited to, ongoing or active infection,
             symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guopei Zhu</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai 9th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengjin Dou, MD</last_name>
    <phone>15800386875</phone>
    <email>doushengjin@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai ninth people's hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</investigator_affiliation>
    <investigator_full_name>Guopei Zhu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <keyword>High-Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

